Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listCefixime

Cefixime

  • CAS NO.:79350-37-1
  • Empirical Formula: C16H15N5O7S2
  • Molecular Weight: 453.45
  • MDL number: MFCD03788802
  • EINECS: 616-684-4
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-05 08:26:49
Cefixime Structural

What is Cefixime?

Absorption

About 40%-50% absorbed orally whether administered with or without food, however, time to maximal absorption is increased approximately 0.8 hours when administered with food.

Toxicity

Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting.

Description

Cefixime is the first orally active third-generation cephalosponn with a true broad spectrum of activity. It is reportedly more effective against Gram-negative bacteria than conventional oral cephems such as cephalexin and cefaclor.

Chemical properties

Pale Yellow Solid

Chemical properties

Cefixime is an oral third generation cephalosporin antibiotic. It was sold under the trade name Suprax in the United States until 2003. The oral suspension form of “Suprax” was re-launched. Cefixime is prescribed for bacterial infections of the chest, ears, urinary tract, and throat (tonsilitis and pharyngitis), and for uncomplicated gonorrhea, upper and lower respiratory tract infections, acute otitis media, and gonococcal urethritis.

Originator

Fujisawa (Japan)

The Uses of Cefixime

Orally active, third generation cephalosporin antibiotic

The Uses of Cefixime

Cephalosporin antibacterial

The Uses of Cefixime

Orally active, third generation cephalosporin antibiotic.

Indications

For use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: (1) uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis, (2) otitis media caused by Haemophilus influenzae (beta-lactamase positive and negative strains), Moraxella catarrhalis (most of which are beta-lactamase positive), and S. pyogenes, (3) pharyngitis and tonsillitis caused by S. pyogenes, (4) acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae (beta-lactamase positive and negative strains), and (5) uncomplicated gonorrhea (cervical/urethral) caused by Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains).

What are the applications of Application

Cefixime is third generation cephalosporin antibiotic

Background

Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.

Definition

ChEBI: A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea tonsilitis, pharyngitis, bronchitis, and urinary tract infections.

Manufacturing Process

To a suspension of 7-amino-3-vinyl-3-cephem-4-carboxylic acid (11.25 g), 2- (aminothiazol-4-yl)-2-(tert-butoxycarbonylmethoxyimino)acetic acid S-mercaptobenzothiazole ester (23.88 g) in ethylacetate (266 ml) and water (9 ml) at 2°C is added triethylamine. After completion of the reaction, water is added and pH is adjusted to 2.1 with diluted sulfuric acid. The phases are separated and the aqueous phase is extracted with ethylacetate. The organic extracts are combined and concentrated to a volume of 120 ml, then acetonitrile (100 ml) and formic acid (22 ml) are added. The mixture is stirred at 30-35°C for 1 hour. The mixture is cooled to 2°C, the precipitate is filtered, washed with acetonitrile and dried to obtain 20.86 g of 5-thia-1- azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-(2-amino-4- thiazolyl)(carboxymethoxy)imino)acetylamino)-3-ethenyl-8-oxo-, (6R,7R)- (Cefixime).

brand name

Suprax(Lupin);Cefspan.

Therapeutic Function

Antibiotic

Antimicrobial activity

It is active against N. gonorrhoeae, M. catarrhalis, H. influenzae and a wide range of enterobacteria, including most strains of Citrobacter, Enterobacter and Serratia spp. Its antistaphylococcal activity is poor. It is not active against Acinetobacter spp., Ps. aeruginosa or B. fragilis. It is resistant to hydrolysis by common β-lactamases.

Health Hazard

Exposures to cefi xime may cause side effects that include, but are not limited to, stomach and abdominal pain, diarrhea, vomiting, mild skin rash, headache, fever, urticaria, pruritis, eosinophilia, leucopenia, anaphylaxis, superinfection, hemolytic anemia, dyspepsia, and fl atulence. Also, cefi xime may cause transient elevation of SGOT, SGPT, alkaline phosphatase, BUN, and creatinine. Reports have indicated that cefi xime is mainly excreted unchanged in the bile and urine

Pharmacokinetics

Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.

Pharmacokinetics

Oral absorption: c. 50%
Cmax 400 mg oral: 4–5.5 mg/L after 4 h
Plasma half-life: 3-ndash;4 h
Volume of distribution: 0.1 L/kg
Plasma protein binding: 60-ndash;70%
Absorption and distribution
Oral absorption is slow and incomplete, but is unaffected by aluminum magnesium hydroxide. Penetration into cantharides blister fluid was very slow but exceeded the plasma level. CSF concentrations are poor even in the presence of meningeal inflammation, reaching an average of around 0.22 mg/L in children with meningitis.
Metabolism and excretion
It is not metabolized and is excreted unchanged in urine (mainly by glomerular filtration) and in bile, in which concentrations exceeding 100 mg/L have been found. Less than 20% of an oral dose is recovered from the urine over 24 h, falling to less than 5% in patients with severe renal impairment, with a corresponding increase in plasma concentration. It is not removed by peritoneal or hemodialysis.

Clinical Use

Cefixime has been used successfully in uncomplicated cystitis, upper and lower respiratory tract infections and various other infections. Its failure to provide adequate cover for staphylococci should be noted.

Clinical Use

Cefixime (Suprax) is the first orally active, third-generationcephalosporin that is not an ester prodrug to be approved fortherapy in the United States. Oral bioavailability is surprisinglyhigh, ranging from 40% to 50%. Facilitated transportof cefixime across intestinal brush border membranes involvingthe carrier system for dipeptides may explain itssurprisingly good oral absorption. This result was not expectedbecause cefixime lacks the ionizable α-amino grouppresent in dipeptides and β-lactams previously known to betransported by the carrier system.Cefixime is a broad-spectrum cephalosporin that is resistantto many β-lactamases. It is particularly effective againstGram-negative bacilli, including E. coli, Klebsiella spp., P.mirabilis, indole-positive Proteus, Providencia, and someCitrobacter spp. Most Pseudomonas, Enterobacter, andBacteroides spp. are resistant. It also has useful activityagainst streptococci, gonococci, H. influenzae, and M. catarrhalis.It is much less active against S. aureus. Cefixime isused for the treatment of various respiratory tract infections(e.g., acute bronchitis, pharyngitis, and tonsillitis) and otitismedia. It is also used to treat uncomplicated urinary tract infectionsand gonorrhea caused by β-lactamase–producingbacterial strains.
The comparatively long half-life of cefixime (t1/2 is3–4 hours) allows it to be administered on a twice-a-dayschedule. Renal tubular reabsorption and a relatively high fraction of plasma protein binding (~65%) contribute to thelong half-life. It is provided in two-oral dosage forms: 200-or 400-mg tablets and a powder for the preparation of anaqueous suspension.

Side Effects

It is well tolerated, but diarrhea is fairly common and pseudomembranous colitis has been reported. Other side effects common to cephalosporins are occasionally seen.

Veterinary Drugs and Treatments

Uses for cefixime are limited in veterinary medicine. Its use should be reserved for those times when infections (systemic or urinary tract) are caused by susceptible gram-negative organisms where oral treatment is indicated or when approved fluoroquinolones or other 3rd generation cephalosporins (e.g., cefpodoxime) are either contraindicated or ineffective.

in vitro

previous study found that cefixime was more active than cephalexin, cefaclor, and amoxicillin against various gram-negative bacteria. cefixime was also significantly more active than tested reference drugs against clinical isolates of klebsiella pneumoniae, escherichia coli, indole-positive and -negative proteus species, providencia species, and neisseria gonorrhoeae. moreover, cefixime was active against strains of k. pneumoniae, e. coli, as well as proteus mirabilis resistant to the reference agents [1].

in vivo

the therapeutic activities of cefixime in mice infected with gram-negative bacilli were found to be far superior to the activities of cephalexin, cefaclor, and amoxicillin, but they were inferior to the activities against infection with staphylococcus aureus [1].

Drug interactions

Potentially hazardous interactions with other drugs
Anticoagulants: effects of coumarins may be enhanced.

Metabolism

Hepatic. Approximately 50% of the absorbed dose is excreted unchanged in the urine in 24 hours.

Metabolism

About 20% of an oral dose (or 50% of an absorbed dose) is excreted unchanged in the urine via glomerular filtration within 24 hours. Up to 60% may be eliminated by non-renal mechanisms; there is no evidence of metabolism but some drug is probably excreted into the faeces from bile.

Precautions

Users of cefi xime should be careful in health conditions such as neonates, pregnancy, lactation, and renal failure. Users should follow suitable and appropriate health care measures to control superinfection (if it happens during therapy). It is contraindicated in patients with a known allergy to penicillin or any other ingredients of Taximax. Taxim-O is contraindicated in patients with a known allergy to the cephalosporin group of antibiotics.

References

[1] kamimura, t. ,kojo, h.,matsumoto, y., et al. in vitro and in vivo antibacterial properties of fk 027, a new orally active cephem antibiotic. antimicrobial agents and chemotherapy 25(1), 98-104 (1984).
[2] quintiliani r. cefixime in the treatment of patients with lower respiratory tract infections: results of us

Properties of Cefixime

Melting point: 218-225°C
Density  1.85±0.1 g/cm3(Predicted)
storage temp.  Keep in dark place,Inert atmosphere,2-8°C
solubility  Slightly soluble in water, soluble in methanol, sparingly soluble in anhydrous ethanol, practically insoluble in ethyl acetate.
form  Solid
pka pKa 2.10 (Uncertain)
color  Off-White to Pale Yellow
Water Solubility  55.11 mg/L
Stability: Hygroscopic
CAS DataBase Reference 79350-37-1(CAS DataBase Reference)

Safety information for Cefixime

Signal word Warning
Pictogram(s)
ghs
Exclamation Mark
Irritant
GHS07
GHS Hazard Statements H302:Acute toxicity,oral
H315:Skin corrosion/irritation
H319:Serious eye damage/eye irritation
H335:Specific target organ toxicity, single exposure;Respiratory tract irritation
Precautionary Statement Codes P261:Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Computed Descriptors for Cefixime

Abamectin manufacturer

Hetero Drugs Limited

1Y
Phone:+91-4023704923
product: 79350-37-1 Cefixime 98%
Inquiry

Ralington Pharma

1Y
Phone:+91-9687771722
Whatsapp: +91- 9687771722
product: 79350-37-1 98%
Inquiry

Covalent Laboratories Private Limited (Virchow Group)

1Y
Phone:+919866077161
Whatsapp: +91- 9866077161
product: Cefixime 98%
Inquiry

Concept Pharmaceuticals Ltd

1Y
Phone:+91-2242418888
product: Cefixime 79350-37-1 99%
Inquiry

Unimark Remedies Ltd

1Y
Phone:+91-2267304120
product: Cefixime 99%
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.